Key references: Management of diabetic retinopathy
American Diabetes Association. 10. Microvascular complications and foot care: Standards of medical care in diabetes-2018. Diabetes Care 2018;41(Suppl 1):S105–18. https://www.ncbi.nlm.nih.gov/pubmed/29222381
Craig ME, Twigg SM, Donaghue K, Cheung NW, Cameron FJ. National evidence-based clinical care guidelines for type 1 diabetes for children, adolescents and adults. Canberra: Australian Department of Health and Ageing; 2011. www.diabetessociety.com.au/position-statements.asp
Diabetes Canada Clinical Practice Guidelines Expert CommitteeAltomare F, Kherani A, Lovshin J. Retinopathy. Can J Diabetes 2018;42 Suppl 1:S210–6. https://www.ncbi.nlm.nih.gov/pubmed/29650099
Hanna S, Optometry Australia Diabetes Guidelines Working Group. Optometry Australia - Guidelines on the examination and management of patients with diabetes. Clin Exp Optom 2016;99(2):120–6. https://www.ncbi.nlm.nih.gov/pubmed/26928922
Levin A, Duncan
L, Djurdjev O, Shapiro RJ, Frohlich J, Belanger A, et al. A randomized
placebo-controlled double-blind trial of lipid-lowering strategies in patients
with renal insufficiency: diet modification with or without fenofibrate. Clin
Nephrol 2000;53(2):140-6. https://www.ncbi.nlm.nih.gov/pubmed/10711416
Simo R, Hernandez C. Prevention and treatment of diabetic retinopathy: evidence from large, randomized trials. The emerging role of fenofibrate. Rev Recent Clin Trials 2012;7(1):71–80. https://www.ncbi.nlm.nih.gov/pubmed/21864248
Stitt AW, Curtis TM, Chen M, Medina RJ, McKay GJ, Jenkins A, et al. The progress in understanding and treatment of diabetic retinopathy. Prog Retin Eye Res 2016;51:156–86. https://www.ncbi.nlm.nih.gov/pubmed/26297071
Wong TY, Simo R, Mitchell P. Fenofibrate - a potential systemic treatment for diabetic retinopathy? Am J Ophthalmol 2012;154(1):6–12. https://www.ncbi.nlm.nih.gov/pubmed/22709833
